Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GJB2 | P29033 | 8/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | GJA1 | P17302 | 5/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25914408 | 0.94 | GJB2 (0.49) | GJB2SLC6A2GJA1 | |
| SCHEMBL25913957 | 0.87 | TP53 (0.47) | GJB2SLC6A2GJA1NT5E | |
| SCHEMBL25913809 | 0.86 | PTPN1 (0.47) | GJB2SLC6A2NT5E | |
| SCHEMBL21128352 | 0.83 | PTPN1 (0.45) | GJB2NT5E | |
| SCHEMBL25031771 | 0.81 | GJB2 (0.53) | GJB2SLC6A2GJA1NT5E | |
| SCHEMBL13608236 | 0.80 | PTPN1 (0.53) | GJB2SLC6A2NT5E | |
| SCHEMBL4982234 | 0.77 | SLC6A2 (0.51) | GJB2SLC6A2NT5E | |
| SCHEMBL6809787 | 0.77 | GJB2 (0.58) | GJB2SLC6A2GJA1NT5E | |
| SCHEMBL9853872 | 0.77 | GJB2 (0.58) | GJB2SLC6A2GJA1NT5E | |
| SCHEMBL9853868 | 0.77 | GJB2 (0.58) | GJB2SLC6A2GJA1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218766-A1 | SUGAR COMPOUND HAVING POLYETHYLENE GLYCOL CHAIN, AND PRECURSOR OF ANTIBODY-DRUG COMPLEX | THE NOGUCHI INSTITUTE (JP) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218766-A1 | SUGAR COMPOUND HAVING POLYETHYLENE GLYCOL CHAIN, AND PRECURSOR OF ANTIBODY-DRUG COMPLEX | FCGRT, HBZ, FUT4 | GJB2 2030/4885SLC6A2 912/4885GJA1 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.